NEW YORK (GenomeWeb News) – NewBridge Pharmaceuticals today announced an agreement to offer Verinata Health's non-invasive prenatal tests in the Middle East and surrounding areas.

Under the exclusive agreement, NewBridge will offer Verinata's Verifi test in the Middle East, Africa, Turkey, and Caspian regions. Financial terms of the deal were not disclosed.

Based in Dubai, United Arab Emirates, NewBridge is a specialty therapeutics firm that commercializes pharmaceuticals, biologics, diagnostics, and medical devices in the Middle East and neighboring areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.